Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda announces new data on candesartan

Takeda announces new data on candesartan

15th September 2008

Takeda has announced the presentation of new data on the effect of candesartan in diabetic eye complications.

This information was presented at the annual congress of the European Association of the Study of Diabetes in Rome.

Data from over 5,000 patients involved in the Direct programme were shown at he event, with the results showing a strong trend in favour of treatment with the angiotensin receptor blocker in reducing the incidence of diabetic retinopathy in type 1 diabetes patients.

However, these results were not statistically significant, with the trial therefore missing its primary endpoints, though a significant increase in regression of diabetic retinopathy was observed in type 2 diabetes patients.

Professor Anne Katrin Sjolie, chair of the Direct steering committee, said: “Despite the fact that the trials did not meet the primary endpoints, the data show encouraging results for candesartan treated patients.”

She added that the Direct programme broke new ground through its focus on the early stages of diabetic complications with the goal of protecting against the worsening of these conditions.

In March 2008, Takeda Pharmaceutical reported on the efficacy of a fixed dose combination of Blopress (candesartan cilexetil) and hydrochlorochlorothiazide as a treatment for hypertension.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.